Skip to main content

Table 4 Analysis of adverse reactions

From: A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer

Adverse events

Experimental group (N = 40)

Control group (N = 18)

合计(N = 58)

At least one adverse reaction occurred

22 (55.00%)

17 (94.44%)

39 (67.24%)

χ2

8.77

 

P

0.003

 

Vomiting

17 (42.50%)

10 (55.56%)

27 (46.55%)

Bone marrow suppression

8 (20.00%)

12 (66.67%)

20 (34.48%)

diarrhea

5 (12.50%)

0 (0.00%)

5 (8.62%)

Fever

1 (2.50%)

2 (11.11%)

3 (5.17%)

Anemia

1 (2.50%)

1 (5.56%)

2 (3.45%)

Hypokalemia

1 (2.50%)

0 (0.00%)

1 (1.72%)

Myocardial ischemia

0 (0.00%)

1 (5.56%)

1 (1.72%)

dizziness

1 (2.50%)

0 (0.00%)

1 (1.72%)

Decreased platelets

1 (2.50%)

0 (0.00%)

1 (1.72%)